Ipamorelin 5mg

Ipamorelin 5mg is a synthetic pentapeptide growth hormone secretagogue (GHS) designed for research and laboratory use. Ipamorelin acts as a selective agonist of the ghrelin receptor (GHS-R1a), stimulating pulsatile growth hormone release from anterior pituitary somatotrophs with high selectivity and minimal effect on cortisol, prolactin, or ACTH — distinguishing it from earlier GHRPs such as GHRP-6. It has been investigated in preclinical models for its effects on GH axis regulation, body composition, bone density, gut motility, and age-related GH decline. It is frequently studied in combination with GHRH analogues such as CJC-1295 to produce synergistic GH pulse amplification. Each vial is manufactured to pharmaceutical-grade purity standards to ensure consistency and reliability in research settings. Ideal for qualified researchers and institutions studying GHS-R1a pharmacology, GH secretion dynamics, and metabolic regulation. Store at 2–8°C. For research purposes only. Not intended for human or veterinary use.

Specifications: Active Ingredient: Ipamorelin Concentration: 5mg per vial Peptide Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂ Molecular Formula: C₃₈H₄₉N₉O₅ Molecular Weight: 711.85 g/mol Classification: Selective GHS-R1a agonist (ghrelin receptor agonist) Selectivity: Highly selective for GH secretion; minimal ACTH, cortisol, or prolactin stimulation Purity: ≥98% (HPLC) Form: Lyophilised powder Endotoxin Level: <5 EU/vial Storage: 2–8°C (refrigerated) Shelf Life: 24 months from manufacture date Reconstitution: Bacteriostatic water Intended Use: Laboratory and research applications only

Storage Before Reconstitution: Store in original sealed vial at 2–8°C, away from light and moisture. Stable for 24 months from manufacture date. Storage After Reconstitution: Store reconstituted solution at 2–8°C and use within 21 days. Do not freeze reconstituted solution. Minimise light exposure. For research use only. Not intended for human or veterinary use.

Research References

The following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.

1. Ipamorelin: Discovery as the First Selective GH Secretagogue
   Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
   The foundational characterisation study establishing ipamorelin as the first highly selective GH secretagogue, demonstrating potent GH release with minimal effect on ACTH, cortisol, and prolactin in rat models — distinguishing it from GHRP-6 and GHRP-2 and establishing its selectivity profile for GH-axis research.
2. Ipamorelin and GHS-R1a Receptor Pharmacology
   Howard AD, et al. (1996). A receptor in pituitary and hypothalamus that functions in growth hormone release. Science, 273(5277), 974–977. https://doi.org/10.1126/science.273.5277.974
   Reports the cloning and characterisation of GHS-R1a — the primary molecular target of ipamorelin — establishing the receptor biology and signal transduction pathways through which ipamorelin stimulates pulsatile GH secretion from anterior pituitary somatotrophs.
3. Ipamorelin and Postoperative Gut Motility
   Poitras P, et al. (2005). Ipamorelin, a ghrelin mimetic, stimulates gastrointestinal motility in postoperative ileus in rats. Neurogastroenterology & Motility, 17(6), 892–901. https://doi.org/10.1111/j.1365-2982.2005.00699.x
   Demonstrates ipamorelin’s ability to stimulate gastrointestinal motility and accelerate recovery from postoperative ileus in rat models via GHS-R1a activation in the enteric nervous system, expanding its research scope beyond the GH axis into gastrointestinal biology.
4. Ipamorelin and Bone Density in Preclinical Models
   Svensson J, et al. (2000). Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. (See also: Johansen PB, et al. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2), 106–113.) https://doi.org/10.1054/ghir.1999.9998
   Demonstrates ipamorelin-induced longitudinal bone growth and increased bone mineral density in rat models via GH/IGF-1 axis stimulation, providing key preclinical data for researchers investigating GHS-R1a agonism in skeletal biology and bone metabolism.
5. Ipamorelin + CJC-1295 Synergy: Combined GH Secretagogue Research
   Teichman SL, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
   Provides the pharmacodynamic basis for combining GHRH analogues with GHS-R1a agonists such as ipamorelin, demonstrating synergistic amplification of GH pulse amplitude — the key reference for researchers designing combination CJC-1295 + ipamorelin protocols.

All references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.